Working… Menu

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04980872
Recruitment Status : Recruiting
First Posted : July 28, 2021
Last Update Posted : September 23, 2021
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA)-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS).

Condition or disease Intervention/treatment Phase
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) Drug: Miransertib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Multicenter
Masking: None (Open Label)
Masking Description: None (Open-label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label, Phase 2, Extension Trial to Study the Long-term Safety in Participants With PROS or Proteus Syndrome Who Are Currently Being Treated With Miransertib in Other Studies
Estimated Study Start Date : October 12, 2021
Estimated Primary Completion Date : August 30, 2025
Estimated Study Completion Date : August 30, 2025

Arm Intervention/treatment
Experimental: Miransertib
Participants with either PROS or PS receive miransertib orally once daily between 5 and 35 mg/m^2 based on prior approved dosing for up to 48 cycles. A cycle is 28 days long.
Drug: Miransertib
Miransertib capsules administered orally either 1 hour before or 2 hours after a meal.
Other Names:
  • MK-7075
  • ARQ 092

Primary Outcome Measures :
  1. Number of participants experiencing a Serious Adverse Event (SAE) [ Time Frame: Up to approximately 4 years ]
    An SAE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An SAE can therefore be any such event that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalizations, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is considered by the investigator to be an important medical event.

  2. Number of participants discontinuing study treatment due to an Adverse Event (AE) [ Time Frame: Up to approximately 4 years ]
    An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product and does not imply any judgment about causality.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 120 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Has PROS or PS and is currently being actively treated with miransertib as part of Study MK-7075-002 (NCT03094832) or ArQule's Compassionate Use and Extended Access Program (CU/EAP, NCT03317366)

Exclusion Criteria:

  • Has previously discontinued miransertib due to related SAEs or other intolerance of miransertib
  • Received other investigational agents, if any, that were administered between leaving Study MK-7075-02 or ArQule's CU/EAP and entering this trial
  • Receives inhibitors of the mechanistic target of rapamycin (mTOR) pathway (eg, sirolimus, everolimus)
  • Receives immunosuppressive therapies
  • Receives continuous high dose steroids

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04980872

Layout table for location contacts
Contact: Toll Free Number 1-888-577-8839

Layout table for location information
Australia, Queensland
Bundaberg Base Hospital ( Site 0202) Recruiting
Bundaberg, Queensland, Australia, 4670
Contact: Study Coordinator    +61741502222      
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Layout table for investigator information
Study Director: Medical Director Merck Sharp & Dohme Corp.
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT04980872    
Other Study ID Numbers: 7075-006
MK-7075-006 ( Other Identifier: Merck )
2021-001369-19 ( EudraCT Number )
First Posted: July 28, 2021    Key Record Dates
Last Update Posted: September 23, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Merck Sharp & Dohme Corp.:
ARQ 092
Congenital malformations
Additional relevant MeSH terms:
Layout table for MeSH terms
Proteus Infections
Proteus Syndrome
Pathologic Processes
Enterobacteriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Hamartoma Syndrome, Multiple
Neoplasms, Multiple Primary
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Limb Deformities, Congenital
Musculoskeletal Abnormalities
Abnormalities, Multiple
Congenital Abnormalities